[Vytorin vs. Lipitor] Merck executives wants to advertise the drug Vytorin to compete Pfizer's Lipitor. Merck believes that Vytorin is superior to its rival, Lipitor. To test their belief, Merck conducted a 24 week study with 788 patients (n1=n2=394) and measured the percentage reduction in cholesterol from a baseline of untreated patients. The results are recorded in the table below: Vytorin Lipitor Sample size 394 394 Sample mean 50 % 37% Sample stdev 10 % 16.53 % Meanwhile, the marketing department came up with the following statement for their advertisement: "With dual inhibition, Vytorin is superior to Lipitor (atorvarstatin). The clinical study shows that the average % reduction of LDC counts with Vytroin is greater by at least 11 percentage points than with Lipitor" Is there evidence that the difference in means greater than 11%? 14. [2 pts] Describe the parameter you will be testing a hypothesis test for and state the appropriate null and alternative hypotheses for the purpose of your analysis. Parameter: Ho: HA